Poolbeg Pharma to present at key industry conferences in March and April 2025

 () , a clinical-stage biopharma company focused on infectious diseases, issued a brief update on CEO Jeremy Skillington's upcoming participation in three major industry conferences, scheduled for March and April 2025.

The conferences in question are the Master Investor Show on March 29, BioTrinity on April 2, and LSX World Congress on April 30. All three will be held in London. To schedule a meeting with the Poolbeg team, interested parties can email ir@poolbegpharma.com. The exact location and times are as follows:

Master Investor Show - Business Design Centre, London, UK
March 29, Showcase Stage (Ground Floor), 1.00pm - 1.10pm
Poolbeg will be located at Booth M30.

BioTrinity - Convene, 133 Houndsditch, London, UK
April 2, Science Spotlight 8 - Rare Disease, 9.30am - 11am
Poolbeg's presentation will focus on its drug candidate POLB 001, an oral preventative therapy for cancer immunotherapy-induced CRS.

LSX World Congress - Business Design Centre, London, UK
30 April, 2pm
Panel title: "Thriving Amidst Turbulence: Building Resilience in Life Sciences"

The Master Investor Show is the UK's largest event for private investors. It will commence on March 29 this year, giving approximately 5,000 investors direct exposure to company CEOs and industry experts and insiders.

BioTrinity is OBN's flagship annual two-day conference for the life sciences industry. Now in its 19th edition, this year's programme will feature a dual track of presentations from R&D companies across 14 different therapy areas, a full business and investment track, sponsors exhibition, networking events, private partnering meetings, and an academic poster presentation.

Around 900 delegates are expected to attend BioTrinity this year, comprising a mix of early-stage and emerging life sciences R&D companies, investors, big pharma, academics, charities, and government.

The LSX World Congress is a major European partnering, strategy, and investment event, with qualified 1:1 partnering at its core. The event gathers senior life science industry decision-makers from the world's leading biopharma, medtech and healthtech companies with investors, senior BD&L teams, R&D leaders and industry KOLs.

Poolbeg is expected to present data related to its flagship anti-inflammatory candidate POLB 001. The asset is a Phase 2-ready oral drug, proved effective in reducing Cytokine Release Syndrome (CRS) associated with cancer immunotherapies. Due to CRS risk, administration of such cancer treatments is currently restricted to specialist centres, which limits their uptake. As an oral therapy to prevent or treat CRS, POLB 001 has the potential to enable broader use of cancer immunotherapies in an outpatient setting.

Poolbeg recently shared excellent data related to POLB 001 from a pre-clinical in vivo study, a mouse model of immunotherapy-induced CRS. The study evaluated the effect of POLB 001 on CRS compared to Adalimumab, an anti-TNF antibody which is the gold standard inhibitor of CRS in humanised tumour-bearing mouse models. The study showed that POLB 001 effectively reduced CRS and demonstrated superior cytokine inhibition compared to Adalimumab.

The positive results further reinforced the use case for POLB 001 in the prevention and treatment of CRS. Next, investors can look forward to Phase 2 clinical studies. As mentioned, an effective drug for CRS has the potential to make cancer immunotherapies more tolerable and widely accessible, and enable patients to fully benefit from their treatment. Delivering an effective oral drug for CRS will therefore be a significant value inflection point for Poolbeg, with POLB 001 having a 3rd party-estimated market potential of US$10bn.

As of its most recent interim results,  remains well-funded with over £10m in cash despite significant investment in its candidates, positioning it well for further growth.

Follow News & Updates from Poolbeg Pharma: